Yuri Jeong1, Min-Ho Shin2, Sang Min Yoon3, Gi-Won Song4, Ki-Hun Kim2, Chul-Soo Ahn2, Deok-Bog Moon2, Shin Hwang2, Jin-Hong Park1, Jong Hoon Kim1, Sung-Gyu Lee2. 1. Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 2. Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 3. Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. drsmyoon@amc.seoul.kr. 4. Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. drsong71@amc.seoul.kr.
Abstract
PURPOSE: The study aims to analyze the oncologic outcomes of living donor liver transplantation (LDLT) after combined transarterial chemoembolization (TACE) and radiotherapy for hepatocellular carcinoma (HCC) with major vascular invasion. METHODS: We retrospectively reviewed 17 HCC patients with major vascular invasion who underwent LDLT after combined treatment modality between May 2007 and September 2014. The LDLT timing was determined by the surgeons depending on the disease status and liver function. The intrahepatic recurrence-free survival, disease-free survival (DFS), and overall survival (OS) rates were estimated from the date of the LDLT. RESULTS: The median follow-up period was 24.5 months (range, 6.4-66.0 months) after the LDLT. The interval between the combined treatment and the LDLT was a median of 5 months (range, 0.4-65.3 months). On the explanted liver, total necrosis was shown in five patients (29.4 %). The 1- and 3-year DFS rates were 70.6 and 57.8 %, respectively. The 1- and 3-year OS rates were 87.4 and 60.5 %, respectively. The major pattern of failure was distant metastasis (35.3 %), and intrahepatic recurrence occurred in three patients (17.6 %) who experienced distant metastasis. CONCLUSIONS: In the selected HCC patients with major vascular invasion, LDLT after combined TACE and radiotherapy showed acceptable oncologic outcomes.
PURPOSE: The study aims to analyze the oncologic outcomes of living donor liver transplantation (LDLT) after combined transarterial chemoembolization (TACE) and radiotherapy for hepatocellular carcinoma (HCC) with major vascular invasion. METHODS: We retrospectively reviewed 17 HCC patients with major vascular invasion who underwent LDLT after combined treatment modality between May 2007 and September 2014. The LDLT timing was determined by the surgeons depending on the disease status and liver function. The intrahepatic recurrence-free survival, disease-free survival (DFS), and overall survival (OS) rates were estimated from the date of the LDLT. RESULTS: The median follow-up period was 24.5 months (range, 6.4-66.0 months) after the LDLT. The interval between the combined treatment and the LDLT was a median of 5 months (range, 0.4-65.3 months). On the explanted liver, total necrosis was shown in five patients (29.4 %). The 1- and 3-year DFS rates were 70.6 and 57.8 %, respectively. The 1- and 3-year OS rates were 87.4 and 60.5 %, respectively. The major pattern of failure was distant metastasis (35.3 %), and intrahepatic recurrence occurred in three patients (17.6 %) who experienced distant metastasis. CONCLUSIONS: In the selected HCC patients with major vascular invasion, LDLT after combined TACE and radiotherapy showed acceptable oncologic outcomes.
Authors: Kathy Han; George N Tzimas; Jeffrey S Barkun; Peter Metrakos; Jean L Tchervenkov; Nir Hilzenrat; Phil Wong; Marc Deschênes Journal: Can J Gastroenterol Date: 2007-01 Impact factor: 3.522
Authors: Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton Journal: Liver Transpl Date: 2006-08 Impact factor: 5.799
Authors: Sung Hoon Yang; Kyung-Suk Suh; Hae Won Lee; Eung-Ho Cho; Jai Young Cho; Yong Beom Cho; Nam-Joon Yi; Kuhn Uk Lee Journal: Liver Transpl Date: 2006-11 Impact factor: 5.799
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: Sang Min Yoon; Young-Suk Lim; Hyung Jin Won; Jong Hoon Kim; Kang Mo Kim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee; Sung Gyu Lee; Jin-Hong Park; Dong Jin Suh Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-27 Impact factor: 7.038
Authors: Jun Luo; Rong-Ping Guo; Eric C H Lai; Yao-Jun Zhang; Wan Yee Lau; Min-Shan Chen; Ming Shi Journal: Ann Surg Oncol Date: 2010-09-14 Impact factor: 5.344
Authors: William C Chapman; M B Majella Doyle; Jourdan E Stuart; Neeta Vachharajani; Jeffrey S Crippin; Christopher D Anderson; Jeffrey A Lowell; Surendra Shenoy; Michael D Darcy; Daniel B Brown Journal: Ann Surg Date: 2008-10 Impact factor: 12.969